Summary Small cell lung cancer (SCLC) is treated primarily with combination chemotherapy. Despite high initial response rates, most patients eventually die with drug resistant disease. In some tumours, resistance to multiple chemotherapeutic agents is attributed to overexpression of P-glycoprotein (P-gp). However, this does not appear to be a frequent occurrence in drug resistant SCLC. Increased levels of glutathione (GSH) and related enzymes may play a role in resistance to alkylating agents as well as natural product drugs. We measured levels of GSH, glutathione S-transferase (GST), glutathione reductase (GSH Red), glutathione peroxidase (GSH Px), and y-glutamyl transpeptidase (y-GT) in a panel of 20 SCLC cell lines. Most of these lines were established from patients treated at this centre. Each cell line had a characteristic and reproducible profile of GSH and related enzyme levels. Immunoblot analysis indicated that the predominant GST in the cell lines was the anionic isoenzyme. The relative sensitivity of each of these cell lines to 16 different chemotherapeutic agents was measured using a modified MTT assay. Spearman rank correlation analysis was used to determine the relationships between the relative chemosensitivity of these cell lines and the levels of GSH and related enzymes. The number of positive correlations was no greater than expected by chance alone. Furthermore, there was no correlation with the treatment history of the patients from whom the cell lines were derived. These data suggest that alterations in glutathione metabolism do not play a major role in resistance to chemotherapeutic agents in these human SCLC cell lines.
Small cell lung cancer (SCLC) comprises about 25% of bronchogenic carcinomas. This tumour has many clinical and pathological features which distinguish it from the other major types of lung cancer, collectively referred to as non small cell lung cancer (NSCLC) (Cohen & Matthews, 1978) . Chemotherapy is the primary modality of therapy in SCLC. Treatment usually consists of combination chemotherapy, including agents such as cyclophosphamide, doxorubicin, vincristine, VP-16, and either cisplatin or carboplatin. Response rates of up to 90% can be achieved with combination chemotherapy, and a small proportion of patients are probably cured (Seifter & Ihde, 1988) .
Despite impressive initial responses to chemotherapy, the majority of patients eventually succumb to their disease, and the major reason for treatment failure is the acquisition of resistance to multiple chemotherapeutic agents (multidrug resistance). The most frequently described alteration in multidrug resistant cells of various tumour types is the overexpression of a plasma membrane protein, termed P-glycoprotein (P-gp), which serves to actively export drugs from cells (Bradley et al., 1988) . Although P-glycoprotein overexpression has been detected in some multidrug resistant SCLC lines (Reeve et al., 1989; Minato et al., 1990) , other multidrug resistant SCLC cell lines do not overexpress this drug efflux pump (Mirski et al., 1987; Cole et al., 1991; de Jong et al., 1990; Nygren et al., 1991) . Furthermore, studies of large numbers of SCLC cell lines and clinical samples indicate that P-gp overexpression does not occur frequently in this disease (Lai et al., 1989; Noonan et al., 1990; Milroy et al., 1992) . Consequently, there has been interest in other potential mechanisms of multidrug resistance in SCLC.
Increasing attention has focused on the role of glutathione and glutathione-related enzymes in drug resistance. Glutathione (GSH) is a tripeptide thiol which plays a critical role in protection of cells from the toxic effects of radiation, oxygen radicals, endogenous toxins, and xenobiotics. GSH and its associated enzymes have been implicated in resistance to alkylating agents Buller et al., 1987; Waxman, 1990 ) and platinum compounds (Teicher et al., 1987; Hospers et al., 1988; Meijer et al., 1990; Saburi et al., 1989) . As well, they may play a role in resistance to natural product drugs which are part of the multidrug resistance phenotype (Batist et al., 1986; Kramer et al., 1988) , although this has been questioned (Yusa et al., 1988) .
In SCLC, the evidence implicating alterations in GSH metabolism in drug resistance is inconclusive. Changes in levels of GSH and related enzymes have been found in certain SCLC cell lines which have undergone in vitro selection for drug resistance (Cole et al., 1990; Meijer et al., 1990) . However, it is unclear whether these differences are functionally related to the drug resistance phenotype. Others have studied these enzymes in large collections of lung cancer cell lines (Morstyn et al., 1984; Carmichael et al., 1988c) . While differences between NSCLC and SCLC lines were found, the results for lines derived from untreated patients were similar to those from treated patients (Carmichael et al., 1988c) . Furthermore, no relationship was found between levels of glutathione and related enzymes and radiation senstivity profiles of lung cancer cell lines (Morstyn et al., 1984) . Thus, while many groups have examined GSH and related enzymes in small cell and other lung cancers, the involvement of these cellular detoxification mechanisms in drug resistance in these tumours remains uncertain.
The purpose of the present investigation was to examine the relationship between the levels of GSH and related enzymes, and the drug sensitivity profiles of a large panel of SCLC cell lines, as well as the treatment histories of the patients from whom the cell lines were derived. For these studies, a collection of 20 SCLC cell lines was used. These cell lines do not overexpress P-gp as detected using the polymerase chain reaction (Campling, Cole and Gerlach, unpublished results) . The levels of GSH, and associated enzymes GST, GSH Px, GSH Red and 'y-GT were measured in these lines. Multivariate statistical analysis was employed to correlate the drug sensitivity profiles of the cell lines, and the treatment history of the patients from whom the lines were derived, with their levels of GSH and related enzymes.
Cell lines
The properties of the 20 SCLC cell lines used in these studies are summarised in Table I . The conditions for establishing and maintaining the cell lines have been described (Campling et al., 1992) . Twelve of the cell lines were established in this laboratory. The histologic features of the majority of these lines have been described (Campling et al., 1992 (Campling et al., 1992) .
All of the lines were grown in RPMI 1640 medium supplemented with hydrocortisone (10nM), insulin (10fgml-'), transferrin (10 f.g ml-1), estradiol (10 nM), and selenium (30 nM) (HITES medium) and 2.5% FBS. They were maintained in 5% CO2 in a humidified atmosphere at 37°C. The treatment that the patients had received at the time that the cell lines were established is indicated in (Campling et al., 1991) LG-T Lymph node UT CAV,VP/CP-CR This laboratory (Campling et al., 1991) HG-E Pleural effusion UT UT-PD This laboratory (Campling et al., 1991) JO-E Pleural effusion CAV,VP/CP,RT UT-PD This laboratory (Campling et al., 1991) WL-E Pleural effusion VP/CP,CAV
UT-PD
This laboratory (Campling et al., 1991) tested included doxorubicin, amsacrine, carboplatin, cisplatin, 4-hydroperoxy-cyclophosphamide, daunomycin, epirubicin, melphalan, menogaril, mitomycin-C, mitoxantrone, nitrogen mustard, vinblastine, vincristine, VM-26, and VP-16. The response of the individual cell lines to each of the drugs tested was expressed as the area under the dose response curve (AUC) (Lam et al., 1990) .
Assays for glutathione and related enzymes Cells from logarithmically growing cultures were harvested and used for these assays. Protein determinations were performed by the Lowry method as modified by Peterson (1977) for all assays except for the y-GT assay, for which a one reagent method was used (BioRad, Richmond, CA).
The levels of total reduced and oxidised GSH were measured using a modification of the method of Tietze, (1969) , with DTNB as a substrate. The assay was performed in microtiter plates, and the rate of colour formation at 410 nm was recorded. Results are expressed as .tg GSH mg' protein.
GST, GSH Red, and GSH Px assays were performed on cell cytosols prepared by sonicating 1-2 x 107 cells for three 15 s pulses with a 30 s pause between pulses, followed by centrifugation at 100,000 g at 4'C for 20 min.
Total GST was measured using the method of Immunodetection of GST isoenzymes Cytosolic preparations that had been assayed for GST activity were frozen at -20°C and used later for immunodetection of GST 7r, a, and ft. Cytosolic proteins (50 gg) were separated by electrophoresis on a 15% polyacrylamide gel (Laemmli, 1970) . Purified human placental GST (No. isoenzyme) and rat liver GST (x and 1i isoenzymes) were included as controls. Proteins were transferred overnight to Immobilon-P (Millipore, Mississauga, Ontario) at 100 mA according to the memnod of Towbin et al. (1979) . The blots were then blocked with 5% skim milk in TBS for 1 h. Antibodies to GST x, A, and a were diluted 1:5000 in TBS. The membranes were incubated with either pooled anti-GST-a and I, or anti GST-t in 3% BSA/5% NGS/TBS for 1 h. The blots were incubated with alkaline phosphataseconjugated goat anti-rabbit secondary antibody (1:8000) in 3% BSA/5% NGS/TBS. Immunodetection was performed using nitroblue tetrazolium and bromochloroindolyl phosphate as substrates (Cole et al., 1990 (Morrison, 1976) .
Correlation with treatment status To correlate the results of GSH and related enzymes with the treatment status of the patients from whom the cell lines were derived, the cell lines were classified as 'treated' or 'untreated' with chemotherapy, on the basis of the clinical information in Table I . The mean values for cell lines from treated patients were compared to the mean values for cell lines from untreated patients. Because of the skewed distribution of the data, the Wilcoxan rank sum (or Mann-Whitney U) test was used to make this comparison (Armitage & Berry, 1987; SAS Institute Inc., 1990) .
Results

Drug sensitivity testing
The results of chemosensitivity testing for 16 of the cell lines (NCI-H69, H69AR, NCI-H128, NCI-H209, Mar, SHP-77, AD-A, BK-T, LG-T, HG-E, JO-E, WL-E, JN-M, SH-A, RG-1, and MM-1) have been published previously (Campling et al., 1991) . The results with the remaining four cell lines (LD-T, MO-A, OS-A, and SV-E) are summarised in Table  II . The results are expressed as area under the dose response curve, calculated using the trapezoidal method as described (Lam et al., 1990) . It can be seen that these four cell lines are quite similar in terms of response to the various drugs. The previously reported 16 cell lines represent a wider range of drug responsiveness.
Glutathione and related enzyme levels The levels of GSH, GST, GSH Px, GSH Red and y-GT in the 20 cell lines are shown in Table III m-amsacrine response and levels of GSH Px, using hydrogen peroxide (r = 0.60, P = 0.006) and cumene hydroperoxide (r = 0.50, P = 0.03) as substrates. Scatter plots corresponding to the 96 correlations made in this study did not show any apparent non-linear relationships between the variables.
With a total of 96 correlations to be considered in this study, correlation coefficients exceeding 0.66 are considered significant using the Bonferroni method. The conclusions of the Bonferroni simultaneous tests lead to a more cautious assessment of the strengths of the relationships between the assays and the drug sensitivity results. However, the Bonferroni approach may be excessively conservative, and thus the P value for each individual correlation is also given in Table   IV .
We have also correlated levels of these various enzymes with themselves (data not shown). The total GSH levels correlated with GSH Px activity measured with both H202 (r = 0.49, P = 0.02) and cumene hydroperoxide (r = 0.42, P = 0.05) as substrates. In addition, GSH Red correlated with y-GT levels (r = 0.49, P = 0.02). The GSH Px levels using the two different substrates, H202 and cumene hydroperoxide, were highly correlated (r = 0.90, P = 0.0001).
Correlation with treatment status The GSH and associated enzyme levels in the cell lines derived from treated patients were compared to those derived from untreated patients. There were no significant differences between the two groups of cell lines (data not shown).
Fresh SCLC tumour samples and early passage cell lines Both of the fresh tumour samples consisted of more than 90% tumour cells. The results of assays for GSH and related enzymes are shown in Table V . It can be seen that the values obtained are in the same range as for the SCLC cell lines.
The assays were repeated after the samples had been maintained in vitro for several months. It can be seen from Table  V that the values for many of the assays were not stable after prolonged tissue culture. For example, the initial GST level for sample No. 1 was 83.5 nmol min-mg'-protein, but after several months, this level had declined to 20.7 nmol min-' mg-l protein. On the other hand, for sample No. 2, the level of GSH Red increased from 7.74 nmol min-'mg-' protein initially, to 25.6 nmol min' mg-' protein after in vitro culture.
Immunodetection of GST isoenzymes
Immunoblots using antibodies to three subclasses of GST (a, fi and n) were performed on 15 cell lines. The remaining lines had levels of GST that were too low for detection on immunoblots (cell lines OS-A, JO-E and RG-1), or insufficient amounts of cell lysate available at the time (cell lines Mar, SH-A and MO-A).
The results are shown in Figure 1 . The antibody to GST a detected the GST isoenzyme(s) present in human placenta, but not rat liver, and the antibodies to GST a and fm detected GST isoenzymes in rat liver, but not human placenta. It can be seen that the a isoenzyme of GST was present in these 15 cell lines. The a and tL isoenzymes were not detectable in any of these unpurified samples (data not shown). In addition to the SCLC lines, a cell line BH-E is shown in Figure 1 . This line was derived from a recurrent pleural effusion in a patient who was originally diagnosed and treated as SCLC. However, the histology on the cell line derived from this patient showed adenocarcinoma. This cell line was not included in the correlation analysis.
Discussion
Despite the fact that many groups have studied the role of alterations in glutathione metabolism in drug resistant SCLC, the importance of these mechanisms of resistance in this tumour has not been clarified. In this study, The units for GSH are lg ml-' protein.
All enzyme levels are expressed as nmol min-' mg-' protein. o"?, %Z" significant correlations were found between levels of GSH or its related enzymes and drug sensitivity of these human SCLC cell lines. Furthermore, there were no differences in levels in cell lines derived from treated patients compared to those derived from untreated patients. Thus, our results provide support for the idea that GSH related detoxification mechanisms do not play a major role in drug resistance in SCLC.
In this report, we have examined larger numbers of SCLC lines than previously studied by other investigators. The drug sensitivity profiles of these lines have been extensively characterised, and they display a wide range of drug sensitivity (Campling et al., 1991) . Furthermore, the treatment histories of the patients from whom these lines were obtained are well documented, and they are known to represent a spectrum of clinically drug sensitive and drug resistant tumours. Thus, our results may reflect the clinical situation.
The GST's have been intensively investigated as potential mediators of drug resistance. These enzymes catalyse the conjugation of GSH to electrophilic substances, thus rendering them more water soluble. The observation by Batist et al. (1986) (Buller et al., 1987; Gupta et al., 1989; Armstrong et al., 1992) , nitrosoureas (Ali-Osman et al., 1990) , platinum compounds (Teicher et al., 1987; Nakagawa et al., 1988; Saburi et al., 1989) , and natural product drugs (Whelan et al., 1989; Peters & Roelofs, 1992; Singh et al., 1989) . However, the functional role of GST in drug resistance has been questioned, since many multidrug resistant cell lines do not overexpress this isoenzyme (Yusa et al., 1988) . Furthermore, a multidrug resistant variant of the breast cancer cell line, MCF-7, which overexpresses GST x, retained elevated levels of this enzyme when it reverted to a drug sensitive phenotype (Yusa et al., 1988) .
One of the most direct approaches to resolving the question of whether increased expression of GST alone confers drug resistance is to transfect the gene into drug sensitive cells, and examine the drug response of the transfectants. A number of groups have taken this approach, with variable results. Some have found no changes in drug sensitivity of the transfectants, despite increased levels of GST activity (Moscow et al., 1989; Fairchild et al., 1990) . Others have found GST transfected cells to be resistant to doxorubicin, whereas the effect on sensitivity to alkylating agents has been variable (Nakagawa et al., 1990; Puchalsky & Fahl, 1990; Black et al., 1989) . In general, the levels of resistance detected have been low.
One of the largest studies of the role of GSH metabolism as a determinant of drug sensitivity in lung cancer was that of Carmichael et al. (1988c) , which examined 30 different SCLC and NSCLC cell lines. Significant differences were found between the results for the SCLC compared to the NSCLC lines. They speculated that these alterations could account for the differences in drug sensitivity between these two tumour types. However, a reanalysis of this data by Hosking et al. (1990) showed no correlation between GSH levels and doxorubicin response in these cell lines. Furthermore, no differences were found between results for cell lines from previously untreated and previously treated patients. Our results are in accordance with these findings.
We found that the only detectable GST in our cell lines was the isoenzyme. Others have found that GST is the predominant transferase in normal lung, and is overexpressed in lung tumours (Howie et al., 1990; Awasthi et al., 1987; Carmichael et al., 1988a) .
Although our data do not show significant correlations between drug sensitivity and alterations in GSH metabolism, it is possible that we may have underestimated the importance of these metabolic pathways. In some experimental systems, increased capacity for glutathione synthesis in response to cytotoxic drugs has been demonstrated Lee et al., 1989; Meijer et al., 1990 (Griffith, 1982) , or ethacrynic acid, an inhibitor of GST, are currently underway (O'Dwyer et al., 1991; 1992) . These agents may prove to be beneficial in those tumour types in which alterations in GSH metabolism are clinically important. It appears that ovarian cancer may fall into this category (Andrews et al., 1985; Ozols et al., 1987; Mistry et al., 1991) , but from the data presented here, it appears that SCLC does not. It is quite likely that different tumour types may invoke different cellular protection mechanisms in response to chemotherapy.
The acquisition of resistance to multiple chemotherapeutic agents continues to be the major impediment to cure of SCLC. Despite intensive efforts of many investigators, the solution to this problem has remained elusive. Evidence from many laboratories suggests that P-gp is not a major factor. The data presented here indicate that alterations in GSH metabolism do not likely play a major role.
Attention should now be directed toward investigating other potential mechanisms of multidrug resistance in SCLC, and determining their clinical importance. There is increasing evidence for involvement of the nuclear enzyme, topoisomerase II, in multidrug resistance in SCLC (Long et al., 1986; Zijlstra et al., 1987; de Jong et al., 1990; Binashi et at., 1990; Minato et at., 1990; Cole et al., 1991; Kasahara et al., 1992; Giaccone et al., 1992) . This enzyme is the intranuclear target of many of the drugs which are part of the 'multidrug resistance phenotype'. However, changes in topoisomerase II cannot explain the entire problem of drug resistance in SCLC, since they would not account for resistance to the vinca alkaloids, alkylating agents, or platinum compounds which do not interact with this DNA unknotting enzyme. Thus, drug resistance in this disease may be mul-tifactorial (Cole, 1992) .
Recently, a number of groups have reported changes in subcellular distribution of drugs in multidrug resistant cell lines which do not overexpress P-gp (Gervasoni et al., 1991; Schuurhuis et al., 1991; Marquardt & Center, 1992) . These findings suggest the existence of other transport protein(s) apart from P-gp, which may act by sequestering drugs away from their intracellular targets. The recent isolation of a cDNA encoding a novel ATP-binding cassette transporter protein which is overexpressed in the H69AR cell line may shed light on some of these observations . Further investigation of the role of this transporter in clinically acquired drug resistance in SCLC is warranted. 
